Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
128.8 USD | +0.97% | -0.54% | +17.89% |
May. 02 | Merck: encouraging results in gastric cancer | CF |
May. 01 | Merck Says Keytruda Meets Primary Endpoint in Late-Stage Gastric Cancer Trial | MT |
MarketScreener Strategies
Merck and Company : Leader in oncology, modest valuation | October 29, 2019 at 11:04 am EDT |
- Stock Market
- Equities
- MRK Stock
- News Merck & Co., Inc.
- MarketScreener Strategies